HARBIN, China, May 30 /Xinhua-PRNewswire/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) (“Renhuang” or “the Company”), a leading pharmaceutical company in the People’s Republic of China (“PRC”), today reported solid financial results for the fourth quarter and fiscal year ended October 31, 2007.
Fourth Quarter Fiscal 2007 Highlights
-- Total revenues increased to $7.1 million, up 5% from the fourth
quarter of 2006
-- Gross profit reached $3.6 million, up 19% from the fourth quarter of
2006
-- Gross margin was 51%, up from 45% in the fourth quarter of 2006
-- Operating income totaled $1.1 million
-- Net income was $1.1 million, or $0.03 per diluted share
Full Year 2007 Highlights
-- Total revenues in 2007 were $28.0 million
-- Gross profit in 2007 was $14.3 million
-- Gross margin was 51%
-- Operating income was $9.6 million
-- Net income increased to $9.6 million, or $0.27 per fully diluted share
“This was a very key year for Renhuang Pharmaceuticals. We performed well on promotions and advertisements and enhanced our production processes. We also focused on our best selling product, Acanthopanax, and continued to work with scientific institutions to enhance our research and development capabilities,” said Mr. Shaoming Li, Chairman and CEO of Renhuang. “We will continue to maintain this strategy in the year ahead and plan to explore new markets and increase sales.”
Fourth Quarter 2007 Results
Renhuang’s total revenues in the fourth quarter were $7.1 million, a slight increase of 5% over the fourth quarter of 2006. This was attributed to sales of its Acanthopanax products, which accounted for about 51% of the total revenues
Gross profit in the fourth quarter of 2007 was $3.6 million, an increase of 19% over the fourth quarter of 2006. Gross margin for the quarter increased to 51% from 45% in the fourth quarter of 2006. This decrease in the cost of production is mainly due to improvements in manufacturing procedures that eliminated unnecessary processes.
Operating expenses in the fourth quarter of 2007 were $2.5 million, up 74% from $1.4 million in the fourth quarter of 2006. This increase was due to higher selling, general and administrative expenses (“SG&A”) attributed to the promotion of the Company’s top selling Acanthopanax products. Research and development (“R&D”) expenses also increased, as the Company initiated development of new products.
Operating expenses represented 35% of total revenues in the fourth quarter of 2007, up from 21% in the fourth quarter of 2006.
Operating income was $1.1 million in the fourth quarter of 2007, down 30% from $1.6 million in first quarter of 2007. Operating margin was 15.5%, as compared to 23.5% during the same period a year ago.
Net income for the fourth quarter of 2007 was $1.1 million, or $0.03 per diluted share, down from $1.6 million, or $0.05 per diluted share in the fourth quarter of 2006.
“During the fourth quarter, we experienced a slight decrease in our net income due to the increase in SG&A and R&D expenses. However, we remain optimistic in our ability to deliver outstanding results for our investors, as we expect to commercialize new products soon, and for our investments in our top selling product, Acanthopanax, to yield increased market share,” concluded Mr. Li.
Full Year 2007 Results
For the full year 2007, total revenues were $28.0 million. Gross profit for the full year 2007 was $14.3 million. Gross profit margin was 51% in 2007. Operating income was $9.6 million in 2007. Operating margin was 34% in 2007. Net income for 2007 was $9.6 million or $0.27 per diluted share.
Financial Condition
As of October 31, 2007, Renhuang had approximately $10.2 million in cash and equivalents. Working capital was about $18.8 million, compared to $7.8 million as of October 31, 2006. Stockholders’ equity as of October 31, 2007 was $21.4 million, an increase of 101% over the $10.6 million recorded as of October 31, 2006. For the fiscal year ended October 31, 2007, cash provided by operating activities was $8.9 million.
Comparability of Results
On September 7, 2006, the Company completed a share exchange transaction through which it acquired Harbin Renhuang Pharmaceutical Company Limited (“Old Renhuang”) and its wholly owned subsidiary, Harbin Renhuang Pharmaceutical Co., Ltd. (“Renhuang China”). The Company was deemed to be the acquirer for accounting purposes. Therefore, the financial statements in this press release are those of Renhuang China for all periods prior to the acquisition on September 7, 2006 and the financial statements of the consolidated companies from the acquisition date forward. On December 5, 2006, the Company changed its fiscal year end from April 30 to October 31. Therefore, the Company’s Annual Report on Form 10-K for the period ended October 31, 2006 was a transition report, and included information for the six-month transitional period from May 1, 2006 to October 31, 2006. As a result, this press release includes comparative financial information for the statement of income and statement of cash flows for the six month period ended October 31, 2006, and not for the twelve months ended October 31, 2006.
About Renhuang Pharmaceuticals, Inc.
Founded in 1996, Renhuang Pharmaceuticals, Inc, produces western, traditional Chinese medicines (TCM), and branded pharmaceuticals, using its GMP-certified facilities in China. The Company’s GMP-certified manufacturing facilities, containing cutting-edge technologies and advanced equipment, are capable of producing as many as 200 types of pharmaceuticals. Additionally, Renhuang distributes raw materials and finished pharmaceutical products using its extensive distribution channels and third party distributors throughout China. The Company’s distribution network includes approximately 25 independent sales distributors, representing over 3,000 sales representatives in 70 sales centers across 24 districts, covering over 50% of the greater China. The Company also exports its products to Russia and Southeast Asia. For more information, visit http://www.renhuang.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
- FINANCIAL TABLES FOLLOW-
RENHUANG PHARMACEUTICALS, INC. AND SUBSIDIARIES
Unaudited Consolidated Statements of Operations
Three Months Ended October 31,
2007 2006
Revenues $ 7,149,518 $ 6,833,614
Cost of Goods Sold (3,508,912) (3,783,774)
Gross Profit 3,640,606 3,049,840
Operating Expenses
Selling and distribution expenses (31,943) (211,487)
Advertising expenses (1,178,631) (677,390)
General and administrative (1,261,108) (369,878)
Research and development (282,009) (121,272)
Provision for doubtful accounts 312,448 18,793
Depreciation and amortization (79,957) (88,909)
Income from operations 1,119,406 1,599,697
Other income 18,353 3,502
Income Before Provision for Income Tax 1,137,759 1,603,199
Net Income (Loss) $ 1,137,759 $ 1,603,199
Basic Earnings Per Share $ 0.03 $ 0.05
Diluted Earnings Per Share $ 0.03 $ 0.05
Basic Weighted Average Shares
Outstanding 35,039,310 35,000,181
Diluted Weighted Average Shares
Outstanding 35,039,550 35,000,181
RENHUANG PHARMACEUTICALS, INC. AND SUBSIDIARIES
Audited Consolidated Statements of Operations
Year Ended Six Months Ended
October 31, 2007 October 31, 2006
Revenues $ 28,040,174 $ 12,247,489
Cost of Goods Sold (13,693,892) (6,143,277)
Gross Profit 14,346,282 6,104,212
Operating Expense:
Selling and distribution expenses (166,567) (299,484)
Advertising expenses (1,358,900) (677,390)
General and administrative (2,553,541) (657,574)
Research and development (282,009) (121,272)
Provision for doubtful accounts (130,634) --
Depreciation and Amortization (293,637) (131,760)
Income from operations 9,560,994 4,216,732
Other Income 35,638 8,482
Income Before Income Taxes 9,596,632 4,225,214
Net Income $ 9,596,632 $ 4,225,214
Basic Earnings Per Share $ 0.27 $ 0.12
Diluted Earnings Per Share $ 0.27 $ 0.12
Basic Weighted Average Shares Outstanding 35,039,310 35,000,181
Diluted Weighted Average Shares
Outstanding 35,039,550 35,000,181
RENHUANG PHARMACEUTICALS, INC. AND SUBSIDIARIES
Audited Consolidated Balance Sheets
October 31, 2007 and 2006
2007 2006
Current Assets
Cash and cash equivalents $ 10,153,603 $ 1,021,267
Accounts receivable, net 10,480,549 7,566,096
Inventories 969,672 622,144
Prepayments 9,917 102,473
Other receivables, net 669,445 1,143,834
Deferred expenses -- 115,823
Total current assets 22,283,186 10,571,637
Property and equipment, net 2,606,285 2,610,285
Construction in process -- 106,610
Total Assets $ 24,889,471 $ 13,288,532
Current Liabilities
Accounts payables
-due to related parties $ -- $ 419,910
-due to third parties 188,600 366,805
Other payables
-due to related parties
-due to third parties 3,307,371 1,877,042
Total current liabilities 3,495,971 2,663,757
Total Liabilities 3,495,971 2,663,757
Stockholders' Equity
Common stock-Authorized common shares
100,000,000, outstanding number of shares
35,096,681 (35,000,181 in 2006) at par
value of 0.001; authorized preferred
shares 1,000,000 outstanding number of
share nil (nil in 2006) 35,097 35,000
Additional paid-in capital 6,627,099 6,310,822
Reserves 1,841,734 847,133
Retained earnings 11,980,112 3,378,081
Accumulated other comprehensive income 909,458 53,739
Total stockholders' equity 21,393,500 10,624,775
Total Liabilities and Shareholders'
Equity $ 24,889,471 $ 13,288,532
RENHUANG PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended Six Months Ended
October 31, 2007 October 31, 2006
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $9,596,632 $4,225,214
Adjustments to reconcile net income
from operations to net cash from
operating activities
Depreciation and amortization 293,637 131,760
Provision for bad debts 444,609 --
Fair value of warrants issued 31,699 --
Fair value of shares issued 284,675 --
Changes in assets and liabilities:
Accounts receivable (2,574,916) (7,566,096)
Inventories (305,926) (622,144)
Other receivables, net 206,548 (1,143,834)
Due from Related Parties (430,146) --
Deferred expenses 118,647 (115,823)
Prepayments 95,325 (102,473)
Accounts payable and accruals
-Related Parties -- 419,910
-Third Parties (191,388) 366,805
Other Payable 1,306,967 1,877,042
NET CASH (USED IN) PROVIDED BY
OPERATING ACTIVITIES 8,876,363 (2,529,639)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property, plant and
equipment (45,741) (76,800)
Construction in progress -- (106,610)
NET CASH PROVIDED BY INVESTING
ACTIVITIES (45,741) (183,410)
CASH FLOWS FROM FINANCING ACTIVITIES:
Increase of paid-in capital -- 3,680,577
Due to related parties -- --
NET CASH PROVIDED BY (USED IN)
FINANCING ACTIVITIES -- 3,680,577
NET INCREASE IN CASH AND CASH
EQUIVALENTS 8,830,622 967,528
EFFECT OF EXCHANGE RATE CHANGES ON CASH
AND CASH EQUIVALENTS 301,714 53,739
CASH - beginning of year 1,021,267 --
CASH - end of year 10,153,603 1,021,267
SUPPLEMENTAL DISCLOSURE OF CASH FLOW
INFORMATION:
Issuance of common shares for
financing services 284,675 --
Warrants of 25,000 granted to a
director for services 31,699 --
Property, plant and equipment
received from shareholders as part
of paid-in capital -- 2,665,245
